An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma
Relapsed/Refractory Multiple Myeloma
DRUG: ICI201
Dose limiting toxicity (DLT), Dose limiting toxicity (DLT), Time Frame: 28 days post ICI201 administration|Incidence and severity of all adverse events related to study drug, Incidence and severity of all adverse events related to study drug, Time Frame: 2 years post ICI201 administration
An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma